Physician profile
Romana Usman
NPI 1538200852
$1,867.23
in general payments reported to CMS, 2019-2025
24 companies · $81.59 in 2025
The $81.59 reported for 2025 was less than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,298 · 2020: $182 · 2021: $150 · 2022: $64.72 · 2024: $90.87 · 2025: $81.59.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $172.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $172.46 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Daiichi Sankyo INC. | $315.02 | 2019-2020 | |
| Viiv Healthcare Company | $227.01 | 2019-2020 | |
| Gilead Sciences, INC. | $213.69 | 2019-2021 | |
| Glaxosmithkline, LLC. | $123.84 | 2019-2025 | Trelegy Ellipta, Shingrix, Arexvy |
| Sanofi-Aventis U.S. LLC | $119.90 | 2019-2022 | |
| Abbvie INC. | $106.27 | 2019-2021 | |
| Merck Sharp & Dohme LLC | $96.35 | 2019-2025 | Capvaxive, Gardasil 9 |
| Astrazeneca Pharmaceuticals LP | $96.22 | 2019-2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $90.32 | 2019-2021 | |
| Novartis Pharmaceuticals Corporation | $87.84 | 2019 | |
| Lilly USA, LLC | $85.50 | 2019-2025 | Mounjaro, Zepbound |
| Novo Nordisk INC | $54.78 | 2019-2024 | Rybelsus, Ozempic |
| Pfizer INC. | $30.08 | 2019-2020 | |
| Mannkind Corporation | $29.86 | 2019 | |
| Exact Sciences Corporation | $27.98 | 2024 | Cologuard Collection Kit |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astellas Pharma US INC | $23.67 | 2019 | |
| Biodelivery Sciences International, INC. | $22.60 | 2019 | |
| Circassia INC. | $19.38 | 2020 | |
| Biohaven Pharmaceuticals, INC. | $18.23 | 2021 | |
| Biohaven Pharmaceutical Holding Company LTD. | $17.56 | 2022 | |
| Amgen INC. | $17.43 | 2020 | |
| Vyera Pharmaceuticals, LLC | $16.45 | 2019 | |
| Janssen Biotech, INC. | $15.68 | 2019 | |
| Arbor Pharmaceuticals, INC. | $11.57 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Romana Usman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.